Replying to @AndrewDudum
@AndrewDudum can we get a Hims Research Lab. similiar to @RoResearchLab ? I think it’s a massive opportunity long term.
13
Petrelintide provides two things: ~10% weight loss in 42 weeks, and THE best trial name in the game (ZUPREME!).
One thing you won’t get? Nausea and vomiting, which was very similar to placebo... nice #ObesityWeek2026 #OW2026
6
355
Our abstract on GLP-1 access gaps was covered in the AMJC Journal. Read more about it below 👀 #OW2026 #ObesityWeek
Could GLP-1s play a bigger role in cancer survivorship? We're exploring the possibilities.
Weight gain is a common side effect of some cancer treatments, and maintaining a healthy weight is an important part of life after cancer. While GLP-1s may offer a promising option for weight management, more research is needed to understand whether GLP-1 treatment or weight loss could help reduce the risk of cancer recurrence.
That's where real-world data can help. We collaborated with @AmericanCancer Society to explore how Ro's data could support future research on GLP-1s among cancer survivors. After further review, we found that cancer survivors make up a meaningful proportion of Ro’s patient population, highlighting an opportunity to help close these research gaps.
Research shows that being metabolically healthier is crucial to helping ward off cancer recurrence, and we see an opportunity for Ro Research Lab to help lead the way in answering important questions about GLP-1s, metabolic health, and life after cancer. #OW2026 #obesityweek2026
We always learn so much from @ljaronne. His latest teachings?
1. Berobenatide helped patients lose ~12% weight loss over 28 weeks on a monthly injection.
2. “Berobenatide” is pronounced: 🐻-🅾️-BEN-🅰️-🌊
#ObesityWeek2026 #OW2026
4
281
Think telehealth can’t serve patients across the BMI spectrum? Think again.
In the first-of-its-kind study, we partnered with Drs. @pshauerMD and Vance Albaugh at @pbrcnews and Dr. @bevtchangMD at @WeillCornell Medical School to examine treatment outcomes among patients with a BMI of 50 or higher.
Released at @ObesityWeek today, we found that among 500 Ro patients who remained engaged in GLP-1 treatment (semaglutide or tirzepatide) for one year, the average weight loss was 19.4% (~67 pounds).
The results highlight the potential for clinically significant weight loss through telehealth-based GLP-1 treatment among patients with some of the greatest treatment needs. As the figure shows, over 80% of patients moved to a lower BMI category, but most still had a BMI of greater than 40.
That's a major achievement, but there's an opportunity to do even more. For these patients, surgical procedures and new medications with different mechanisms of action (e.g., CagriSema, retatrutide) will continue to advance the field, ultimately helping patients, regardless of size, on their weight loss journeys. #OW2026 #ObesityWeek
2
2
121
The internet: "Only people with a really high BMI should be on a GLP-1”
The data: 🤨🤨🤨
Among Ro patients with BMI 25+, food noise looked almost identical across the spectrum.
Someone seeking treatment with a BMI of 27 was struggling with food noise just as often as someone with a BMI of 47.
Research clearly shows — and our data suggests — that exercise is associated with other benefits aside from weight loss.
Ro patients who reported engaging in more exercise early on in their GLP-1 treatment were also more likely to report more energy, improved mood, better sleep, and fewer cravings at higher rates at month one:
1
1
5
We assessed weight loss at the first month of treatment while controlling for other factors such as age, starting body mass index (BMI), and sex.
The results still held: Cardio was not significantly associated with early weight loss, while more frequent strength training was associated with less weight loss (which reflects potential greater preservation of muscle mass- always a good thing, as seen in the RCT in Nature Medicine).
1
2
36
About two weeks into treatment, we asked Ro Body patients how much they had been exercising since they started taking a GLP-1 and then tracked their weight.
As you can see from the chart below, the amount of exercise didn’t seem to make much of a difference.
1
1
68
We created your new favorite tool, the Ro GLP-1 Pipeline Tracker.
The obesity drug pipeline is moving fast and getting crowded and keeping track of players, drugs, trials and readouts can be a full time job. Use this tool to track every drug, it's studies, efficacy, side effects, timeline, and search by company, drug, and class.
Tell us what's missing, and we'll build it in (because we love you and don't want you to have to live with 40 tabs open).
ro.co/research-lab/tools/glp…
So… who cares if you exercise?
The gym barely moved the needle for Ro Body patients in the first 60 days of GLP-1 treatment: Patients lost about 5% of their body weight regardless of how many hours they spent working out.
1
2
125




















